Blood miR-7-5p levels decrease more rapidly in Parkinson's disease patients than in healthy controls.

This longitudinal cohort study from the Parkinson's Progression Markers Initiative (PPMI) included 303 de novo people with Parkinson's disease (PwP) and 159 healthy controls (HCs). The study examined blood miR-7-5p levels over time, comparing them between groups and assessing correlations with clinical measures.

The main finding was that miR-7-5p levels decreased more rapidly in PwP compared to HCs (p = 0.02). Additionally, miR-7-5p levels correlated with time in the study (p = 0.02). Secondary outcomes included scores on the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) for motor and total scores, and serum neurofilament light chain (NfL) levels.

Safety and tolerability were not reported, as no adverse events, serious adverse events, discontinuations, or tolerability data were provided. The study did not report effect sizes or absolute numbers for the main results.

Key limitations include the observational design, which cannot establish causality, and the lack of reported effect sizes or absolute numbers. The follow-up duration was not reported, and funding or conflicts of interest were not disclosed.

In practice, these findings suggest a potential association between declining blood miR-7-5p levels and Parkinson's disease progression, but they are preliminary and require replication in larger, controlled studies before any clinical application.